Immune Checkpoint Inhibitors Market 2028 By Type, Application and Geography | The Insight Partners

    Immune Checkpoint Inhibitors Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor); Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Other Applications) and Geography

    Report Code: TIPRE00003749 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

    MARKET OVERVIEW



    Immune checkpoint inhibitors are a type of immunotherapy drugs. Targeted immune therapies are becoming conventional treatments for advanced-stage cancers, despite the fact that traditional chemotherapeutic medications remain the first-line option for most cancer types. These drugs stimulate the immune system's recognition and killing of cancer cells by targeting cell surface checkpoint proteins. The key drivers for the immune checkpoint inhibitors market are, increasing prevalence of cancer across the globe along with development of novel targeted therapies for management of cancers.

    MARKET SCOPE



    The "Global Immune Checkpoint Inhibitors Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the immune checkpoint inhibitors market with detailed market segmentation by type and application. The report provides key statistics on the market status of the leading immune checkpoint inhibitors market players and offers key trends and opportunities in the market.

    MARKET SEGMENTATION



    • Based on type the market is segmented as, CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor.
    • Based on application the market is segmented as, lung cancer, bladder cancer, melanoma, hodgkin lumphoma and others.

    MARKET DYNAMICS


    Drivers:



    • Increasing prevalence of cancer across the globe along with development of novel targeted therapies for management of cancers.
    • Growing healthcare expenditures, increasing rates of cancer screening procedures and technological advancements are also expected to fuel the market growth.
    • Growing rates of metastatic and high grade maliganancies.

    Restraints:



    • However, high cost associated with the research and development activities are expected to restrain market growth during the forecast period.

    REGIONAL FRAMEWORK



    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The immune checkpoint inhibitors market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

    The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the immune checkpoint inhibitors market in these regions.

    IMPACT OF COVID-19 ON IMMUNE CHECKPOINT INHIBITORS MARKET
    COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

    MARKET PLAYERS



    The report covers key developments in the immune checkpoint inhibitors market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from immune checkpoint inhibitors market are anticipated to lucrative growth opportunities in the future with the rising demand for immune checkpoint inhibitors in the global market.

    The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the immune checkpoint inhibitors market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

    • AstraZeneca
    • BristolMyers Squibb Company
    • Lilly
    • Fortress Biotech, Inc
    • F. Hoffmann-La Roche Ltd
    • Immutep
    • Merck Sharp and Dohme Corp
    • AbbVie Inc
    • Novartis AG
    • Pfizer Inc.
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
    TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Immune Checkpoint Inhibitors Market - By Type
    1.3.2 Immune Checkpoint Inhibitors Market - By Application
    1.3.3 Immune Checkpoint Inhibitors Market - By Region
    1.3.3.1 By Country

    2. KEY TAKEAWAYS

    3. RESEARCH METHODOLOGY

    4. IMMUNE CHECKPOINT INHIBITORS MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PORTER'S FIVE FORCES ANALYSIS
    4.2.1 Bargaining Power of Buyers
    4.2.1 Bargaining Power of Suppliers
    4.2.1 Threat of Substitute
    4.2.1 Threat of New Entrants
    4.2.1 Competitive Rivalry
    4.3. EXPERT OPINIONS

    5. IMMUNE CHECKPOINT INHIBITORS MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

    6. IMMUNE CHECKPOINT INHIBITORS MARKET - GLOBAL MARKET ANALYSIS
    6.1. IMMUNE CHECKPOINT INHIBITORS - GLOBAL MARKET OVERVIEW
    6.2. IMMUNE CHECKPOINT INHIBITORS - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE

    7. IMMUNE CHECKPOINT INHIBITORS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
    7.1. OVERVIEW
    7.2. TYPE MARKET FORECASTS AND ANALYSIS
    7.3. CTLA-4 INHIBITOR
    7.3.1. Overview
    7.3.2. CTLA-4 Inhibitor Market Forecast and Analysis
    7.4. PD-1 INHIBITOR
    7.4.1. Overview
    7.4.2. PD-1 Inhibitor Market Forecast and Analysis
    7.5. PD-L1 INHIBITOR
    7.5.1. Overview
    7.5.2. PD-L1 Inhibitor Market Forecast and Analysis
    8. IMMUNE CHECKPOINT INHIBITORS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
    8.1. OVERVIEW
    8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
    8.3. LUNG CANCER
    8.3.1. Overview
    8.3.2. Lung Cancer Market Forecast and Analysis
    8.4. BLADDER CANCER
    8.4.1. Overview
    8.4.2. Bladder Cancer Market Forecast and Analysis
    8.5. MELANOMA
    8.5.1. Overview
    8.5.2. Melanoma Market Forecast and Analysis
    8.6. HODGKIN LYMPHOMA
    8.6.1. Overview
    8.6.2. Hodgkin Lymphoma Market Forecast and Analysis
    8.7. OTHER APPLICATIONS
    8.7.1. Overview
    8.7.2. Other Applications Market Forecast and Analysis

    9. IMMUNE CHECKPOINT INHIBITORS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    9.1. NORTH AMERICA
    9.1.1 North America Immune Checkpoint Inhibitors Market Overview
    9.1.2 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis
    9.1.3 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
    9.1.4 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
    9.1.5 North America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
    9.1.5.1 United States Immune Checkpoint Inhibitors Market
    9.1.5.1.1 United States Immune Checkpoint Inhibitors Market by Type
    9.1.5.1.2 United States Immune Checkpoint Inhibitors Market by Application
    9.1.5.2 Canada Immune Checkpoint Inhibitors Market
    9.1.5.2.1 Canada Immune Checkpoint Inhibitors Market by Type
    9.1.5.2.2 Canada Immune Checkpoint Inhibitors Market by Application
    9.1.5.3 Mexico Immune Checkpoint Inhibitors Market
    9.1.5.3.1 Mexico Immune Checkpoint Inhibitors Market by Type
    9.1.5.3.2 Mexico Immune Checkpoint Inhibitors Market by Application
    9.2. EUROPE
    9.2.1 Europe Immune Checkpoint Inhibitors Market Overview
    9.2.2 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis
    9.2.3 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
    9.2.4 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
    9.2.5 Europe Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
    9.2.5.1 Germany Immune Checkpoint Inhibitors Market
    9.2.5.1.1 Germany Immune Checkpoint Inhibitors Market by Type
    9.2.5.1.2 Germany Immune Checkpoint Inhibitors Market by Application
    9.2.5.2 France Immune Checkpoint Inhibitors Market
    9.2.5.2.1 France Immune Checkpoint Inhibitors Market by Type
    9.2.5.2.2 France Immune Checkpoint Inhibitors Market by Application
    9.2.5.3 Italy Immune Checkpoint Inhibitors Market
    9.2.5.3.1 Italy Immune Checkpoint Inhibitors Market by Type
    9.2.5.3.2 Italy Immune Checkpoint Inhibitors Market by Application
    9.2.5.4 Spain Immune Checkpoint Inhibitors Market
    9.2.5.4.1 Spain Immune Checkpoint Inhibitors Market by Type
    9.2.5.4.2 Spain Immune Checkpoint Inhibitors Market by Application
    9.2.5.5 United Kingdom Immune Checkpoint Inhibitors Market
    9.2.5.5.1 United Kingdom Immune Checkpoint Inhibitors Market by Type
    9.2.5.5.2 United Kingdom Immune Checkpoint Inhibitors Market by Application
    9.2.5.6 Rest of Europe Immune Checkpoint Inhibitors Market
    9.2.5.6.1 Rest of Europe Immune Checkpoint Inhibitors Market by Type
    9.2.5.6.2 Rest of Europe Immune Checkpoint Inhibitors Market by Application
    9.3. ASIA-PACIFIC
    9.3.1 Asia-Pacific Immune Checkpoint Inhibitors Market Overview
    9.3.2 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis
    9.3.3 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
    9.3.4 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
    9.3.5 Asia-Pacific Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
    9.3.5.1 Australia Immune Checkpoint Inhibitors Market
    9.3.5.1.1 Australia Immune Checkpoint Inhibitors Market by Type
    9.3.5.1.2 Australia Immune Checkpoint Inhibitors Market by Application
    9.3.5.2 China Immune Checkpoint Inhibitors Market
    9.3.5.2.1 China Immune Checkpoint Inhibitors Market by Type
    9.3.5.2.2 China Immune Checkpoint Inhibitors Market by Application
    9.3.5.3 India Immune Checkpoint Inhibitors Market
    9.3.5.3.1 India Immune Checkpoint Inhibitors Market by Type
    9.3.5.3.2 India Immune Checkpoint Inhibitors Market by Application
    9.3.5.4 Japan Immune Checkpoint Inhibitors Market
    9.3.5.4.1 Japan Immune Checkpoint Inhibitors Market by Type
    9.3.5.4.2 Japan Immune Checkpoint Inhibitors Market by Application
    9.3.5.5 South Korea Immune Checkpoint Inhibitors Market
    9.3.5.5.1 South Korea Immune Checkpoint Inhibitors Market by Type
    9.3.5.5.2 South Korea Immune Checkpoint Inhibitors Market by Application
    9.3.5.6 Rest of Asia-Pacific Immune Checkpoint Inhibitors Market
    9.3.5.6.1 Rest of Asia-Pacific Immune Checkpoint Inhibitors Market by Type
    9.3.5.6.2 Rest of Asia-Pacific Immune Checkpoint Inhibitors Market by Application
    9.4. MIDDLE EAST AND AFRICA
    9.4.1 Middle East and Africa Immune Checkpoint Inhibitors Market Overview
    9.4.2 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis
    9.4.3 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
    9.4.4 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
    9.4.5 Middle East and Africa Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
    9.4.5.1 South Africa Immune Checkpoint Inhibitors Market
    9.4.5.1.1 South Africa Immune Checkpoint Inhibitors Market by Type
    9.4.5.1.2 South Africa Immune Checkpoint Inhibitors Market by Application
    9.4.5.2 Saudi Arabia Immune Checkpoint Inhibitors Market
    9.4.5.2.1 Saudi Arabia Immune Checkpoint Inhibitors Market by Type
    9.4.5.2.2 Saudi Arabia Immune Checkpoint Inhibitors Market by Application
    9.4.5.3 U.A.E Immune Checkpoint Inhibitors Market
    9.4.5.3.1 U.A.E Immune Checkpoint Inhibitors Market by Type
    9.4.5.3.2 U.A.E Immune Checkpoint Inhibitors Market by Application
    9.4.5.4 Rest of Middle East and Africa Immune Checkpoint Inhibitors Market
    9.4.5.4.1 Rest of Middle East and Africa Immune Checkpoint Inhibitors Market by Type
    9.4.5.4.2 Rest of Middle East and Africa Immune Checkpoint Inhibitors Market by Application
    9.5. SOUTH AND CENTRAL AMERICA
    9.5.1 South and Central America Immune Checkpoint Inhibitors Market Overview
    9.5.2 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis
    9.5.3 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Type
    9.5.4 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Application
    9.5.5 South and Central America Immune Checkpoint Inhibitors Market Forecasts and Analysis - By Countries
    9.5.5.1 Brazil Immune Checkpoint Inhibitors Market
    9.5.5.1.1 Brazil Immune Checkpoint Inhibitors Market by Type
    9.5.5.1.2 Brazil Immune Checkpoint Inhibitors Market by Application
    9.5.5.2 Argentina Immune Checkpoint Inhibitors Market
    9.5.5.2.1 Argentina Immune Checkpoint Inhibitors Market by Type
    9.5.5.2.2 Argentina Immune Checkpoint Inhibitors Market by Application
    9.5.5.3 Rest of South and Central America Immune Checkpoint Inhibitors Market
    9.5.5.3.1 Rest of South and Central America Immune Checkpoint Inhibitors Market by Type
    9.5.5.3.2 Rest of South and Central America Immune Checkpoint Inhibitors Market by Application

    10. INDUSTRY LANDSCAPE
    10.1. MERGERS AND ACQUISITIONS
    10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    10.3. NEW PRODUCT LAUNCHES
    10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    11. IMMUNE CHECKPOINT INHIBITORS MARKET, KEY COMPANY PROFILES
    11.1. ASTRAZENECA
    11.1.1. Key Facts
    11.1.2. Business Description
    11.1.3. Products and Services
    11.1.4. Financial Overview
    11.1.5. SWOT Analysis
    11.1.6. Key Developments
    11.2. BRISTOLMYERS SQUIBB COMPANY
    11.2.1. Key Facts
    11.2.2. Business Description
    11.2.3. Products and Services
    11.2.4. Financial Overview
    11.2.5. SWOT Analysis
    11.2.6. Key Developments
    11.3. LILLY
    11.3.1. Key Facts
    11.3.2. Business Description
    11.3.3. Products and Services
    11.3.4. Financial Overview
    11.3.5. SWOT Analysis
    11.3.6. Key Developments
    11.4. FORTRESS BIOTECH, INC
    11.4.1. Key Facts
    11.4.2. Business Description
    11.4.3. Products and Services
    11.4.4. Financial Overview
    11.4.5. SWOT Analysis
    11.4.6. Key Developments
    11.5. F. HOFFMANN-LA ROCHE LTD
    11.5.1. Key Facts
    11.5.2. Business Description
    11.5.3. Products and Services
    11.5.4. Financial Overview
    11.5.5. SWOT Analysis
    11.5.6. Key Developments
    11.6. IMMUTEP
    11.6.1. Key Facts
    11.6.2. Business Description
    11.6.3. Products and Services
    11.6.4. Financial Overview
    11.6.5. SWOT Analysis
    11.6.6. Key Developments
    11.7. MERCK SHARP AND DOHME CORP
    11.7.1. Key Facts
    11.7.2. Business Description
    11.7.3. Products and Services
    11.7.4. Financial Overview
    11.7.5. SWOT Analysis
    11.7.6. Key Developments
    11.8. ABBVIE INC
    11.8.1. Key Facts
    11.8.2. Business Description
    11.8.3. Products and Services
    11.8.4. Financial Overview
    11.8.5. SWOT Analysis
    11.8.6. Key Developments
    11.9. NOVARTIS AG
    11.9.1. Key Facts
    11.9.2. Business Description
    11.9.3. Products and Services
    11.9.4. Financial Overview
    11.9.5. SWOT Analysis
    11.9.6. Key Developments
    11.10. PFIZER INC.
    11.10.1. Key Facts
    11.10.2. Business Description
    11.10.3. Products and Services
    11.10.4. Financial Overview
    11.10.5. SWOT Analysis
    11.10.6. Key Developments

    12. APPENDIX
    12.1. ABOUT THE INSIGHT PARTNERS
    12.2. GLOSSARY OF TERMS
    "
    The List of Companies

    1. AstraZeneca
    2. BristolMyers Squibb Company
    3. Lilly
    4. Fortress Biotech, Inc
    5. F. Hoffmann-La Roche Ltd
    6. Immutep
    7. Merck Sharp and Dohme Corp
    8. AbbVie Inc
    9. Novartis AG
    10. Pfizer Inc.
    TIPRE00003749
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550
        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount